MEN1 and acute leukemia: Menin-MLL inhibitor JNJ-75276617 was initiated a phase 1 study to treat Acute Leukemias, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in 2021(NCT04811560).